Key AstraZeneca lung cancer treatment misses study goal - 3 months ago, 17 Nov 19:38
AstraZeneca (AZN.L) said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.
The study, known as “Mystic”, was among the industry’s most anticipated clinical experiments and was viewed as central to proving the value of the group’s new drug pipeline and its future as an independent company, after it spurned a $118 billion takeover attempt by Pfizer (PFE.N) in 2014.
The trial looked at stage IV patients — those with the most advanced form of cancer.
Results from the final Phase III trial found that Imfinzi (durvalumab) on its own and in combination with tremelimumab did not improve overall survival versus chemotherapy in patients with a protein called PD-L1 on 25 percent or more of their cancer cells.
“We are disappointed that these results missed statistical significance,” said Sean Bohen, ...
Category: topnews news lifestyle health